Elisavet Paplomata

3.3k total citations · 1 hit paper
14 papers, 708 citations indexed

About

Elisavet Paplomata is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Elisavet Paplomata has authored 14 papers receiving a total of 708 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Elisavet Paplomata's work include HER2/EGFR in Cancer Research (5 papers), Cancer Treatment and Pharmacology (5 papers) and Advanced Breast Cancer Therapies (4 papers). Elisavet Paplomata is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Cancer Treatment and Pharmacology (5 papers) and Advanced Breast Cancer Therapies (4 papers). Elisavet Paplomata collaborates with scholars based in United States, United Kingdom and Australia. Elisavet Paplomata's co-authors include Ruth O’Regan, Amelia Zelnak, Ruth O’Regan, Rita Nahta, Lalan S. Wilfong, Ann C. Mertens, Jessica B. Spencer, Amy Fothergill, Penelope P. Howards and Amita K. Manatunga and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Elisavet Paplomata

14 papers receiving 698 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers

2014 452 citations Elisavet Paplomata, Ruth O’Regan Therapeutic Advances in Medical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elisavet Paplomata United States	9	359	307	158	142	52	14	708
Valérie Le Morvan France	18	389 1.1×	310 1.0×	113 0.7×	129 0.9×	74 1.4×	45	745
Aline Hébrant Belgium	14	496 1.4×	241 0.8×	96 0.6×	286 2.0×	72 1.4×	24	895
Paweł Uruski Poland	17	316 0.9×	225 0.7×	86 0.5×	129 0.9×	30 0.6×	52	841
Sarah Sarkar United States	12	486 1.4×	356 1.2×	137 0.9×	268 1.9×	44 0.8×	13	980
Kazuya Kudoh Japan	16	599 1.7×	237 0.8×	93 0.6×	132 0.9×	68 1.3×	48	955
Federica Spadaccino Italy	11	363 1.0×	222 0.7×	197 1.2×	155 1.1×	30 0.6×	19	810
Fubin Feng China	16	379 1.1×	165 0.5×	147 0.9×	264 1.9×	21 0.4×	37	703
Chris Feierabend United States	14	375 1.0×	364 1.2×	129 0.8×	111 0.8×	53 1.0×	27	820
Paola Biason Italy	13	507 1.4×	557 1.8×	163 1.0×	145 1.0×	31 0.6×	21	905
Kai Lee Yap United States	17	481 1.3×	306 1.0×	123 0.8×	203 1.4×	64 1.2×	42	1.0k

Countries citing papers authored by Elisavet Paplomata

Since Specialization

Citations

This map shows the geographic impact of Elisavet Paplomata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisavet Paplomata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisavet Paplomata more than expected).

Fields of papers citing papers by Elisavet Paplomata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisavet Paplomata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisavet Paplomata. The network helps show where Elisavet Paplomata may publish in the future.

Co-authorship network of co-authors of Elisavet Paplomata

This figure shows the co-authorship network connecting the top 25 collaborators of Elisavet Paplomata. A scholar is included among the top collaborators of Elisavet Paplomata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisavet Paplomata. Elisavet Paplomata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Akhter, Nausheen, Elisavet Paplomata, Islam Y. Elgendy, et al.. (2023). Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies. JACC CardioOncology. 5(2). 159–173. 14 indexed citations

Wardley, Andrew, Volkmar Mueller, Elisavet Paplomata, et al.. (2021). Abstract PD13-04: Impact of tucatinib on health-related quality of life in patients with HER2+ metastatic breast cancer with stable and active brain metastases. Cancer Research. 81(4_Supplement). PD13–4. 3 indexed citations

Curigliano, Giuseppe, Volkmar Mueller, Virginia F. Borges, et al.. (2021). Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).. Journal of Clinical Oncology. 39(15_suppl). 1043–1043. 13 indexed citations

Okines, Alicia, Elisavet Paplomata, Tanya A. Wahl, et al.. (2020). Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB).. Journal of Clinical Oncology. 38(15_suppl). 1043–1043. 5 indexed citations

Bercu, Zachary, et al.. (2020). Predictors of Survival after Yttrium-90 Radioembolization of Chemotherapy-Refractory Hepatic Metastases from Breast Cancer. Journal of Vascular and Interventional Radiology. 31(6). 925–933. 16 indexed citations

Paplomata, Elisavet, Amelia Zelnak, Cesar A. Santa‐Maria, et al.. (2019). Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer. Clinical Breast Cancer. 19(3). 188–196. 2 indexed citations

Paplomata, Elisavet & Rita Nahta. (2018). ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer. Expert Opinion on Biological Therapy. 18(3). 335–341. 4 indexed citations

Spencer, Jessica B., Amy Fothergill, Ann C. Mertens, et al.. (2016). Impact of tamoxifen therapy on fertility in breast cancer survivors. Fertility and Sterility. 107(1). 243–252.e5. 54 indexed citations

Paplomata, Elisavet, Rita Nahta, & Ruth O’Regan. (2014). Systemic therapy for early‐stage HER2‐positive breast cancers: Time for a less‐is‐more approach?. Cancer. 121(4). 517–526. 15 indexed citations

10.

Donnelly, Siobhan, Kevin Foy, Robert C. Castellino, et al.. (2014). Insulin-Like Growth Factor-1 Receptor Signaling Increases the Invasive Potential of Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer Cells via Src-Focal Adhesion Kinase and Forkhead Box Protein M1. Molecular Pharmacology. 87(2). 150–161. 34 indexed citations

11.

Paplomata, Elisavet & Ruth O’Regan. (2014). The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Therapeutic Advances in Medical Oncology. 6(4). 154–166. 452 indexed citations breakdown →

12.

Paplomata, Elisavet, Amelia Zelnak, & Ruth O’Regan. (2013). Everolimus: side effect profile and management of toxicities in breast cancer. Breast Cancer Research and Treatment. 140(3). 453–462. 78 indexed citations

13.

Paplomata, Elisavet & Lalan S. Wilfong. (2011). Signet Ring Cell Carcinoma of the Ampulla of Vater With Leptomeningeal Metastases: A Case Report. Journal of Clinical Oncology. 29(21). e627–e629. 17 indexed citations

14.

Paplomata, Elisavet, et al.. (2010). Malakoplakia of the Genitourinary Tract: A Report of 3 Cases. UroToday International Journal. 3(4). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact